Angina pectoris
Angina is pain or discomfort in the chest that happens when too little blood reaches the heart muscle. A US government patient page says it can feel like pressure or squeezing in the chest, and names three types: stable, unstable and variant angina. It calls angina a symptom of coronary artery disease. This page is the umbrella for the angina records in this atlas.
Also called Angina
- Condition
- In this atlas
Overview
Technical summary
MeSH D000787, last updated 2017-06-20, describes angina pectoris as the symptom of paroxysmal pain that follows myocardial ischemia, usually of distinctive character, location and radiation. The patient page is the MedlinePlus angina summary. In the MeSH tree, unstable angina, stable angina and microvascular angina are narrower headings, and variant angina sits under unstable angina. This atlas keeps stable angina and unstable angina as their own records, and microvascular and variant (vasospastic) angina together as one record. Burden figures, treatment and prognosis are outside this record. It carries no clinical review.
Recognition
A US government patient page says angina may feel like pressure or a squeezing pain in the chest, and that not all chest pain or discomfort is angina.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Isosorbide mononitrate
Applies to Recipient not specified People with angina pectoris due to coronary artery disease, as described in the US label of generic isosorbide mononitrate tablets
Population, setting and follow-up
- Patients with angina pectoris due to coronary artery disease, for prevention and treatment, as the indications section of the label states. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of isosorbide mononitrate tablets (ANI Pharmaceuticals, Inc., application ANDA075147; the version dated 2026-03-27 in openFDA) calls isosorbide mononitrate an organic nitrate and a vasodilator with effects on both arteries and veins. It lists the prevention and treatment of angina pectoris due to coronary artery disease, and says the onset of action of the oral medicine is not sufficiently rapid for the product to be useful in aborting an acute anginal episode.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic tablet product; the original brand and other isosorbide mononitrate products were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Nitroglycerin
Applies to Recipient not specified People with angina pectoris due to coronary artery disease, as described in the US label of Nitrostat sublingual tablets
Population, setting and follow-up
- Patients with angina pectoris due to coronary artery disease, for the acute relief or the acute prophylaxis of an attack, as the indications section of the label states. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Nitrostat (nitroglycerin sublingual tablets, Viatris Specialty LLC, application NDA021134; the version dated 2023-02-15 in openFDA) describes the product as a stabilized sublingual compressed nitroglycerin tablet and a nitrate vasodilator. It lists the acute relief of an attack, or acute prophylaxis of an attack, of angina pectoris due to coronary artery disease.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for the sublingual tablet only; other nitroglycerin products were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Ranolazine
Applies to Recipient not specified People with chronic angina, as described in the US label of generic ranolazine extended-release tablets
Population, setting and follow-up
- Patients with chronic angina, as the indications section of the label states. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of ranolazine extended-release tablets (Glenmark Pharmaceuticals Inc., USA, application ANDA211082; the version dated 2026-01-23 in openFDA) lists the treatment of chronic angina and says the tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. The label also says the mechanism of ranolazine's antianginal effects has not been determined. It says ranolazine can inhibit the cardiac late sodium current at therapeutic levels, and that the relationship of this inhibition to angina symptoms is uncertain.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and other ranolazine products were not read. The list of medicines that may be used with it is the label's own statement and is not a recommendation of this atlas. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 62
Record details
- Record id
cardio:angina-pectoris- Content hash
be19c51160fa30963ffdc1be92f496c99ad0cfae7f1067681c2a0c91805f5a06